![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Combination Treatment with HBV-Targeting GalNAc-siRNA and Small-Molecule PD-L1 Inhibitor Increases HBV Specific Immune Responses in a Chronic Hepatitis B Infection Mouse Model
|
|
|
AASLD 2022 Nov 4-8
Emily P Thi, Ingrid Graves, Arpita Mondal, Andrew G Cole, Gavin Heffernan, Christina L Iott, Seyma Ozturk, Sharie C Ganchua, Dan Nguyen, Kim Stever, Kristi Y Fan, Jorge G Quintero, Steven G Kultgen, Amanda Pohl, Troy O Harasym, Angela M Lam, and Michael J Sofia
Arbutus Biopharma Inc., Warminster PA, USA
![1111221](../images/111122/111122-11/1111221.gif)
![1111222](../images/111122/111122-11/1111222.gif)
![1111223](../images/111122/111122-11/1111223.gif)
![1111224](../images/111122/111122-11/1111224.gif)
![1111225](../images/111122/111122-11/1111225.gif)
![1111226](../images/111122/111122-11/1111226.gif)
![1111227](../images/111122/111122-11/1111227.gif)
![1111228](../images/111122/111122-11/1111228.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|